Twist Bioscience (TWST) CEO Reports Sell-to-Cover and Details Large Option Holdings
Rhea-AI Filing Summary
Emily M. Leproust, CEO and Director of Twist Bioscience (TWST), reported a non-discretionary sale and her current holdings. The filing shows a sale of 1,704 shares of Twist common stock on 09/22/2025 at $27.56 per share performed to satisfy tax-withholding required under the company's equity plans. After that transaction she beneficially owns 633,036 shares directly. The form also lists outstanding employee stock options with exercise prices and post-transaction holdings: $5.95 (0), $8.82 (150,879), $26.66 (266,539), $23.33 (131,290) and $67.85 (64,950). The filing notes one set of performance stock options vested and became exercisable on 12/19/2022.
Positive
- Sale was non-discretionary and executed solely to satisfy tax-withholding on vested RSUs, as stated in the filing
- Clear disclosure of option holdings and vesting history, including a performance tranche that vested on 12/19/2022
Negative
- Insider sold shares (1,704 shares) even though the filing clarifies it was to cover taxes
- Significant outstanding option exposure with large share counts at multiple strike prices that could dilute equity upon exercise
Insights
TL;DR: Insider completed a small, mandated sell-to-cover for RSU taxes; substantial option positions remain outstanding.
The Form 4 documents a sale of 1,704 shares at $27.56 on 09/22/2025 explicitly to cover tax withholding tied to RSU vesting, not a discretionary trade. The report confirms direct beneficial ownership of 633,036 shares and large option grants outstanding across multiple strike prices totaling several hundred thousand underlying shares. From an analytical perspective, the filing primarily updates ownership and exercise exposures rather than indicating a change in strategic ownership or control.
TL;DR: Transaction is routine and plan-driven; disclosure aligns with Section 16 reporting requirements.
The sale is described as a company-mandated "sell to cover" to satisfy tax obligations associated with vested restricted stock units, which the filing explicitly states. The form includes full schedules of outstanding options and confirms a performance-based tranche vested on 12/19/2022. Filing is properly signed by an attorney-in-fact and provides clear descriptions of vesting schedules where applicable, meeting typical governance transparency expectations for insider reporting.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,704 | $27.56 | $47K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
FAQ
What did Emily M. Leproust report on Form 4 for TWST?
What employee stock options does the Form 4 disclose for the reporting person?
Did any performance-based awards vest according to the filing?
